Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 114 entries
Sorted by: Best Match Show Resources per page
Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review.

Immune network

Najar M, Krayem M, Meuleman N, Bron D, Lagneaux L.
PMID: 28458620
Immune Netw. 2017 Apr;17(2):89-102. doi: 10.4110/in.2017.17.2.89. Epub 2017 Apr 20.

Mesenchymal Stromal Cells (MSCs) are potential cellular candidates for several immunotherapy purposes. Their multilineage potential and immunomodulatory properties make them interesting tools for the treatment of various immunological diseases. However, depending on the local microenvironment, diverse biological functions of...

Cite
Najar M, Krayem M, Meuleman N, et al. Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. Immune Netw. 2017;17(2):89-102doi: 10.4110/in.2017.17.2.89.
Najar, M., Krayem, M., Meuleman, N., Bron, D., & Lagneaux, L. (2017). Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. Immune network, 17(2), 89-102. https://doi.org/10.4110/in.2017.17.2.89
Najar, Mehdi, et al. "Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review." Immune network vol. 17,2 (2017): 89-102. doi: https://doi.org/10.4110/in.2017.17.2.89
Najar M, Krayem M, Meuleman N, Bron D, Lagneaux L. Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. Immune Netw. 2017 Apr;17(2):89-102. doi: 10.4110/in.2017.17.2.89. Epub 2017 Apr 20. PMID: 28458620; PMCID: PMC5407987.
Copy Download .nbib Format: NLM
Salvage Transoral Laser Microsurgery for Radiorecurrent Laryngeal Cancer: Indications, Limits, and Outcomes.

Current otorhinolaryngology reports

Meulemans J, Delaere P, Nuyts S, Clement PM, Hermans R, Vander Poorten V.
PMID: 28367362
Curr Otorhinolaryngol Rep. 2017;5(1):83-91. doi: 10.1007/s40136-017-0143-7. Epub 2017 Feb 07.

PURPOSE OF REVIEW: The aim of this report is to identify relevant literature reports on salvage transoral laser microsurgery (TLM); to consider its oncologic and functional outcomes, as well as reported complications; and to address indications and limitations of...

Cite
Meulemans J, Delaere P, Nuyts S, et al. Salvage Transoral Laser Microsurgery for Radiorecurrent Laryngeal Cancer: Indications, Limits, and Outcomes. Curr Otorhinolaryngol Rep. 2017;5(1):83-91doi: 10.1007/s40136-017-0143-7.
Meulemans, J., Delaere, P., Nuyts, S., Clement, P. M., Hermans, R., & Vander Poorten, V. (2017). Salvage Transoral Laser Microsurgery for Radiorecurrent Laryngeal Cancer: Indications, Limits, and Outcomes. Current otorhinolaryngology reports, 5(1), 83-91. https://doi.org/10.1007/s40136-017-0143-7
Meulemans, J, et al. "Salvage Transoral Laser Microsurgery for Radiorecurrent Laryngeal Cancer: Indications, Limits, and Outcomes." Current otorhinolaryngology reports vol. 5,1 (2017): 83-91. doi: https://doi.org/10.1007/s40136-017-0143-7
Meulemans J, Delaere P, Nuyts S, Clement PM, Hermans R, Vander Poorten V. Salvage Transoral Laser Microsurgery for Radiorecurrent Laryngeal Cancer: Indications, Limits, and Outcomes. Curr Otorhinolaryngol Rep. 2017;5(1):83-91. doi: 10.1007/s40136-017-0143-7. Epub 2017 Feb 07. PMID: 28367362; PMCID: PMC5357496.
Copy Download .nbib Format: NLM
Investigations in erectile dysfunction.

Current opinion in urology

Meuleman EJ.
PMID: 12917518
Curr Opin Urol. 2003 Sep;13(5):411-6. doi: 10.1097/00042307-200309000-00009.

PURPOSE OF REVIEW: This is an update of recent developments in the investigation of erectile dysfunction in the period since March 2002.RECENT FINDINGS: Three developments in the field of medical sexology redirected the approach towards the investigation of erectile...

Cite
Meuleman EJ. Investigations in erectile dysfunction. Curr Opin Urol. 2003;13(5):411-6doi: 10.1097/00042307-200309000-00009.
Meuleman, E. J. (2003). Investigations in erectile dysfunction. Current opinion in urology, 13(5), 411-6. https://doi.org/10.1097/00042307-200309000-00009
Meuleman, Eric J H. "Investigations in erectile dysfunction." Current opinion in urology vol. 13,5 (2003): 411-6. doi: https://doi.org/10.1097/00042307-200309000-00009
Meuleman EJ. Investigations in erectile dysfunction. Curr Opin Urol. 2003 Sep;13(5):411-6. doi: 10.1097/00042307-200309000-00009. PMID: 12917518.
Copy Download .nbib Format: NLM
European Association of Urology - 15th Congress. Sexual medicine.

IDrugs : the investigational drugs journal

Meuleman E.
PMID: 16080049
IDrugs. 2000 Jul;3(7):766-8.

No abstract available.

Cite
Meuleman E. European Association of Urology - 15th Congress. Sexual medicine. IDrugs. 2000;3(7):766-8
Meuleman, E. (2000). European Association of Urology - 15th Congress. Sexual medicine. IDrugs : the investigational drugs journal, 3(7), 766-8.
Meuleman, E. "European Association of Urology - 15th Congress. Sexual medicine." IDrugs : the investigational drugs journal vol. 3,7 (2000): 766-8.
Meuleman E. European Association of Urology - 15th Congress. Sexual medicine. IDrugs. 2000 Jul;3(7):766-8. PMID: 16080049.
Copy Download .nbib Format: NLM
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.

Critical reviews in oncology/hematology

Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC.
PMID: 21330149
Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16.

Molecular targeted therapies (MTTs) have become a major component of modern management of various hematological and solid malignancies. However, some MTTs have been associated with cardiotoxicity. MTT-induced cardiovascular side effects include left ventricular systolic dysfunction, heart failure, conduction abnormalities,...

Cite
Ederhy S, Izzedine H, Massard C, et al. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011;80(3):369-79doi: 10.1016/j.critrevonc.2011.01.009.
Ederhy, S., Izzedine, H., Massard, C., Dufaitre, G., Spano, J. P., Milano, G., Meuleman, C., Besse, B., Boccara, F., Kahyat, D., Cohen, A., & Soria, J. C. (2011). Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Critical reviews in oncology/hematology, 80(3), 369-79. https://doi.org/10.1016/j.critrevonc.2011.01.009
Ederhy, Stephane, et al. "Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists." Critical reviews in oncology/hematology vol. 80,3 (2011): 369-79. doi: https://doi.org/10.1016/j.critrevonc.2011.01.009
Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16. PMID: 21330149.
Copy Download .nbib Format: NLM
Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues.

Hepatology communications

Vercouter AS, Meuleman P.
PMID: 29404519
Hepatol Commun. 2018 Feb 02;2(2):128-130. doi: 10.1002/hep4.1152. eCollection 2018 Feb.

No abstract available.

Cite
Vercouter AS, Meuleman P. Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues. Hepatol Commun. 2018;2(2):128-130doi: 10.1002/hep4.1152.
Vercouter, A. S., & Meuleman, P. (2018). Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues. Hepatology communications, 2(2), 128-130. https://doi.org/10.1002/hep4.1152
Vercouter, Ann-Sofie, and Meuleman, Philip. "Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues." Hepatology communications vol. 2,2 (2018): 128-130. doi: https://doi.org/10.1002/hep4.1152
Vercouter AS, Meuleman P. Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues. Hepatol Commun. 2018 Feb 02;2(2):128-130. doi: 10.1002/hep4.1152. eCollection 2018 Feb. PMID: 29404519; PMCID: PMC5796321.
Copy Download .nbib Format: NLM
Endoscopic Treatment of Idiopathic Subglottic Stenosis: A Systematic Review.

Frontiers in surgery

Lavrysen E, Hens G, Delaere P, Meulemans J.
PMID: 31998744
Front Surg. 2020 Jan 10;6:75. doi: 10.3389/fsurg.2019.00075. eCollection 2019.

No abstract available.

Cite
Lavrysen E, Hens G, Delaere P, et al. Endoscopic Treatment of Idiopathic Subglottic Stenosis: A Systematic Review. Front Surg. 2020;6:75doi: 10.3389/fsurg.2019.00075.
Lavrysen, E., Hens, G., Delaere, P., & Meulemans, J. (2019). Endoscopic Treatment of Idiopathic Subglottic Stenosis: A Systematic Review. Frontiers in surgery, 675. https://doi.org/10.3389/fsurg.2019.00075
Lavrysen, Emilie, et al. "Endoscopic Treatment of Idiopathic Subglottic Stenosis: A Systematic Review." Frontiers in surgery vol. 6 (2019): 75. doi: https://doi.org/10.3389/fsurg.2019.00075
Lavrysen E, Hens G, Delaere P, Meulemans J. Endoscopic Treatment of Idiopathic Subglottic Stenosis: A Systematic Review. Front Surg. 2020 Jan 10;6:75. doi: 10.3389/fsurg.2019.00075. eCollection 2019. PMID: 31998744; PMCID: PMC6965146.
Copy Download .nbib Format: NLM
In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium.

Pharmaceutics

Bermejo M, Meulman J, Davanço MG, Carvalho PO, Gonzalez-Alvarez I, Campos DR.
PMID: 32560369
Pharmaceutics. 2020 Jun 17;12(6). doi: 10.3390/pharmaceutics12060558.

The aim of the present study was to bring additional evidence regarding a biopredictive dissolution medium containing 1% sodium lauryl sulphate (SLS) to predict the in vivo behavior of carbamazepine (CBZ) products. Twelve healthy volunteers took one immediate release...

Cite
Bermejo M, Meulman J, Davanço MG, et al. In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium. Pharmaceutics. 2020;12(6)doi: 10.3390/pharmaceutics12060558.
Bermejo, M., Meulman, J., Davanço, M. G., Carvalho, P. O., Gonzalez-Alvarez, I., & Campos, D. R. (2020). In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium. Pharmaceutics, 12(6), . https://doi.org/10.3390/pharmaceutics12060558
Bermejo, Marival, et al. "In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium." Pharmaceutics vol. 12,6 (2020). doi: https://doi.org/10.3390/pharmaceutics12060558
Bermejo M, Meulman J, Davanço MG, Carvalho PO, Gonzalez-Alvarez I, Campos DR. In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium. Pharmaceutics. 2020 Jun 17;12(6). doi: 10.3390/pharmaceutics12060558. PMID: 32560369; PMCID: PMC7355855.
Copy Download .nbib Format: NLM
TNM-Classification for Lung Cancer: From the 7(th) to the 8(th) Edition.

Acta chirurgica Belgica

Cogen A, Dockx Y, Cheung KJ, Meulemans E, Lauwers P, Sardari Nia P, Hendriks JM, Van Schil PE.
PMID: 27391544
Acta Chir Belg. 2011 Jan;111(6):389-92. doi: 10.1080/00015458.2011.11680779.

Most tumors are staged according to the Tumor-Node-Metastasis (TNM) classification. For lung cancer a new edition was introduced in 2009 and generally applied since 2010. This 7(th) TNM-classification is based on a large, international retrospective database. Important changes were...

Cite
Cogen A, Dockx Y, Cheung KJ, et al. TNM-Classification for Lung Cancer: From the 7(th) to the 8(th) Edition. Acta Chir Belg. 2011;111(6):389-92doi: 10.1080/00015458.2011.11680779.
Cogen, A., Dockx, Y., Cheung, K. J., Meulemans, E., Lauwers, P., Sardari Nia, P., Hendriks, J. M., & Van Schil, P. E. (2011). TNM-Classification for Lung Cancer: From the 7(th) to the 8(th) Edition. Acta chirurgica Belgica, 111(6), 389-92. https://doi.org/10.1080/00015458.2011.11680779
Cogen, A, et al. "TNM-Classification for Lung Cancer: From the 7(th) to the 8(th) Edition." Acta chirurgica Belgica vol. 111,6 (2011): 389-92. doi: https://doi.org/10.1080/00015458.2011.11680779
Cogen A, Dockx Y, Cheung KJ, Meulemans E, Lauwers P, Sardari Nia P, Hendriks JM, Van Schil PE. TNM-Classification for Lung Cancer: From the 7(th) to the 8(th) Edition. Acta Chir Belg. 2011 Jan;111(6):389-92. doi: 10.1080/00015458.2011.11680779. PMID: 27391544.
Copy Download .nbib Format: NLM
Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.

Oncotarget

Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, Schots R, De Keersmaecker B.
PMID: 29755666
Oncotarget. 2018 Apr 17;9(29):20476-20489. doi: 10.18632/oncotarget.24944. eCollection 2018 Apr 17.

Lenalidomide is a potent anti-myeloma drug with immunomodulatory properties. It is increasingly used in a low-dose maintenance setting to prolong remission duration after standard treatment. Data on the

Cite
Fostier K, Caers J, Meuleman N, et al. Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget. 2018;9(29):20476-20489doi: 10.18632/oncotarget.24944.
Fostier, K., Caers, J., Meuleman, N., Broos, K., Corthals, J., Thielemans, K., Schots, R., & De Keersmaecker, B. (2018). Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget, 9(29), 20476-20489. https://doi.org/10.18632/oncotarget.24944
Fostier, Karel, et al. "Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation." Oncotarget vol. 9,29 (2018): 20476-20489. doi: https://doi.org/10.18632/oncotarget.24944
Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, Schots R, De Keersmaecker B. Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget. 2018 Apr 17;9(29):20476-20489. doi: 10.18632/oncotarget.24944. eCollection 2018 Apr 17. PMID: 29755666; PMCID: PMC5945510.
Copy Download .nbib Format: NLM
Inaccessible LCG Promoters Act as Safeguards to Restrict T Cell Development to Appropriate Notch Signaling Environments.

Stem cell reports

Furuyama S, Wu QV, Varnum-Finney B, Sandstrom R, Meuleman W, Stamatoyannopoulos JA, Bernstein ID.
PMID: 33770495
Stem Cell Reports. 2021 Apr 13;16(4):717-726. doi: 10.1016/j.stemcr.2021.02.017. Epub 2021 Mar 25.

T cell development is restricted to the thymus and is dependent on high levels of Notch signaling induced within the thymic microenvironment. To understand Notch function in thymic restriction, we investigated the basis for target gene selectivity in response...

Cite
Furuyama S, Wu QV, Varnum-Finney B, et al. Inaccessible LCG Promoters Act as Safeguards to Restrict T Cell Development to Appropriate Notch Signaling Environments. Stem Cell Reports. 2021;16(4):717-726doi: 10.1016/j.stemcr.2021.02.017.
Furuyama, S., Wu, Q. V., Varnum-Finney, B., Sandstrom, R., Meuleman, W., Stamatoyannopoulos, J. A., & Bernstein, I. D. (2021). Inaccessible LCG Promoters Act as Safeguards to Restrict T Cell Development to Appropriate Notch Signaling Environments. Stem cell reports, 16(4), 717-726. https://doi.org/10.1016/j.stemcr.2021.02.017
Furuyama, Suzanne, et al. "Inaccessible LCG Promoters Act as Safeguards to Restrict T Cell Development to Appropriate Notch Signaling Environments." Stem cell reports vol. 16,4 (2021): 717-726. doi: https://doi.org/10.1016/j.stemcr.2021.02.017
Furuyama S, Wu QV, Varnum-Finney B, Sandstrom R, Meuleman W, Stamatoyannopoulos JA, Bernstein ID. Inaccessible LCG Promoters Act as Safeguards to Restrict T Cell Development to Appropriate Notch Signaling Environments. Stem Cell Reports. 2021 Apr 13;16(4):717-726. doi: 10.1016/j.stemcr.2021.02.017. Epub 2021 Mar 25. PMID: 33770495; PMCID: PMC8072033.
Copy Download .nbib Format: NLM
Endometriotic lung cyst causing catamenial hemoptysis; a case report and review of literature.

Acta chirurgica Belgica

Verhulst E, Bafort C, Tomassetti C, Wolthuis A, Bielen D, Coolen J, Weynand B, Platteeuw L, Meuleman C, Van Raemdonck D.
PMID: 33657969
Acta Chir Belg. 2021 Mar 04;1-6. doi: 10.1080/00015458.2021.1887556. Epub 2021 Mar 04.

We report a rare case of an endometriotic lung cyst in a 47-year woman with recurrent catamenial hemoptysis. Chest computed tomography (CT) obtained outside the menstruation in October 2019 revealed a cystic lesion (2.5 cm) located in the right...

Cite
Verhulst E, Bafort C, Tomassetti C, et al. Endometriotic lung cyst causing catamenial hemoptysis; a case report and review of literature. Acta Chir Belg. 2021;1-6doi: 10.1080/00015458.2021.1887556.
Verhulst, E., Bafort, C., Tomassetti, C., Wolthuis, A., Bielen, D., Coolen, J., Weynand, B., Platteeuw, L., Meuleman, C., & Van Raemdonck, D. (2021). Endometriotic lung cyst causing catamenial hemoptysis; a case report and review of literature. Acta chirurgica Belgica, 1-6. https://doi.org/10.1080/00015458.2021.1887556
Verhulst, Evelyne, et al. "Endometriotic lung cyst causing catamenial hemoptysis; a case report and review of literature." Acta chirurgica Belgica vol. (2021): 1-6. doi: https://doi.org/10.1080/00015458.2021.1887556
Verhulst E, Bafort C, Tomassetti C, Wolthuis A, Bielen D, Coolen J, Weynand B, Platteeuw L, Meuleman C, Van Raemdonck D. Endometriotic lung cyst causing catamenial hemoptysis; a case report and review of literature. Acta Chir Belg. 2021 Mar 04;1-6. doi: 10.1080/00015458.2021.1887556. Epub 2021 Mar 04. PMID: 33657969.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 114 entries